Login to Your Account

Transition Could Get $130M in Diabetes Deal With Lilly

By Catherine Hollingsworth

Monday, March 17, 2008
Transition Therapeutics Inc. could receive up to $137 million in a deal with drug giant Eli Lilly and Co., which will acquire rights to Transition's gastrin-based therapies for diabetes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription